To expand our observations to a larger panel of NSCLC lines, we tested two of the most efficacious individual siRNAs targeting TPX2 on an additional two SMARCA4-mutant and two SMARCA4-wild-type NSCLC lines. Here, SMARCA4 is linked to non-small cell lung carcinoma.